Evidence map›Paper›PMID 30232272›Full record

ArticleJCI insight2018

IL-33 modulates inflammatory brain injury but exacerbates systemic immunosuppression following ischemic stroke.

Shenpeng R Zhang, Marius Piepke, Hannah X Chu, Brad Rs Broughton, Raymond Shim, Connie Hy Wong, Seyoung Lee, Megan A Evans, Antony Vinh, Samy Sakkal and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Targeting IL-33 in Precision Neuroimmunology: Cellular Mechanisms and Therapeutic Strategies for CNS Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Shenpeng R ZhangCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Marius PiepkeUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hannah X ChuCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Brad Rs BroughtonCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Raymond ShimCentre for Inflammatory Diseases, Department of Medicine, Monash University, Monash Medical Centre, Clayton, Victoria, Australia.
Connie Hy WongCentre for Inflammatory Diseases, Department of Medicine, Monash University, Monash Medical Centre, Clayton, Victoria, Australia.
Seyoung LeeCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Megan A EvansCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Antony VinhCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Samy SakkalCollege of Health and Biomedicine, Victoria University, Western Centre for Health, Research and Education, St. Albans, Victoria, Australia.
Thiruma V ArumugamDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Tim MagnusUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Samuel HuberUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mathias GelderblomUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Grant R DrummondCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Christopher G SobeyCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Hyun Ah KimCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
La Trobe University · AUAustralian Regenerative Medicine Institute · AUUniversität Hamburg · DEMonash Medical Centre · AUNational University of Singapore · SGWestern Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke triggers a complex inflammatory process in which the balance between pro- and antiinflammatory mediators is critical for the development of the brain infarct. However, systemic changes may also occur in parallel with brain inflammation. Here we demonstrate that administration of recombinant IL-33, a recently described member of the IL-1 superfamily of cytokines, promotes Th2-type effects following focal ischemic stroke, resulting in increased plasma levels of Th2-type cytokines and fewer proinflammatory (3-nitrotyrosine+F4/80+) microglia/macrophages in the brain. These effects of IL-33 were associated with reduced infarct size, fewer activated microglia and infiltrating cytotoxic (natural killer-like) T cells, and more IL-10-expressing regulatory T cells. Despite these neuroprotective effects, mice treated with IL-33 displayed exacerbated post-stroke lung bacterial infection in association with greater functional deficits and mortality at 24 hours. Supplementary antibiotics (gentamicin and ampicillin) mitigated these systemic effects of IL-33 after stroke. Our findings highlight the complex nature of the inflammatory mechanisms differentially activated in the brain and periphery during the acute phase after ischemic stroke. The data indicate that a Th2-promoting agent can provide neuroprotection without adverse systemic effects when given in combination with antibiotics.

Indexed as

AnimalsBrain InjuriesBrain IschemiaCytokinesDisease Models, AnimalInflammationInterleukin-10Interleukin-33Interleukin-4LungMacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutMicroglia3-nitrotyrosineCytokinesIL10 protein, mouseIl33 protein, mouseInterleukin-10Interleukin-33Interleukin-4TyrosineCardiologyImmunotherapyInflammationMouse modelsStroke

Identifiers

PMID30232272
PMCPMC6237219
OpenAlexW2889882988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.